Header

UZH-Logo

Maintenance Infos

Diagnosis and Treatment of Primary Aldosteronism in 2017: Did We Achieve Our Goals?


Reincke, Martin; Williams, Tracy Ann; Beuschlein, Felix (2017). Diagnosis and Treatment of Primary Aldosteronism in 2017: Did We Achieve Our Goals? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme, 49(12):905-907.

Abstract

For many decades primary aldosteronism (PA) was dismissed as a rare endocrine condition, but is nowadays widely accepted as the most frequent endocrine cause of hypertension, largely due to the widespread use of the aldosterone-to-renin ratio as a screening test. With a prevalence of 5% of hypertensive subjects in primary care and 10% of hypertensives in referral centers, screening strategies should be extended to designated risk populations, as suggested by several recent national and international guidelines [1] [2] [3]. Primary aldosteronism is highly prevalent in patients with sleep apnea, resistant hypertension (10–30%), and patients with hypokalemic hypertension (>60%). With a growing awareness of the cardiovascular and metabolic comorbidities of sustained aldosterone hypersecretion [4] [5] [6] [7], and the possibility of reversing these consequences through early detection and therapy [8], the diagnosis of PA should be timely.

Abstract

For many decades primary aldosteronism (PA) was dismissed as a rare endocrine condition, but is nowadays widely accepted as the most frequent endocrine cause of hypertension, largely due to the widespread use of the aldosterone-to-renin ratio as a screening test. With a prevalence of 5% of hypertensive subjects in primary care and 10% of hypertensives in referral centers, screening strategies should be extended to designated risk populations, as suggested by several recent national and international guidelines [1] [2] [3]. Primary aldosteronism is highly prevalent in patients with sleep apnea, resistant hypertension (10–30%), and patients with hypokalemic hypertension (>60%). With a growing awareness of the cardiovascular and metabolic comorbidities of sustained aldosterone hypersecretion [4] [5] [6] [7], and the possibility of reversing these consequences through early detection and therapy [8], the diagnosis of PA should be timely.

Statistics

Citations

Altmetrics

Downloads

0 downloads since deposited on 26 Jan 2018
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Endocrinology and Diabetology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:December 2017
Deposited On:26 Jan 2018 15:44
Last Modified:19 Feb 2018 10:34
Publisher:Georg Thieme Verlag
ISSN:0018-5043
OA Status:Closed
Publisher DOI:https://doi.org/10.1055/s-0043-122145
PubMed ID:29202491

Download